The three organizations selected for the 10x Genomics Program are Q2 Solutions, Azenta Life Sciences, and CellCarta.

Incorporating single-cell and spatial capabilities into large-scale clinical research studies can help biopharmaceutical companies predict resistance to therapies in cancer patients and analyze endpoint molecular readouts in cancer trials. Furthermore, single-cell technology can help researchers understand correlative immunological responses to drug therapies, or examine the molecular mechanisms behind vaccine-elicited cell-mediated immunity, among other applications.

The 10x Genomics CRO Program involves a rigorous evaluation of each applicant's capabilities, comprehensive training, and yearly recertification to ensure designated partners meet and maintain a high standard of performance and service excellence, according to the firm. All three global CRO partners bring their own unique expertise to the program.

Q2 Solutions, an Iqvia company, is a clinical trial laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository, biospecimen, and consent-tracking solutions. Azenta Life Sciences is a provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to get to market faster. CellCarta is a provider of specialized precision medicine laboratory services to the biopharmaceutical industry.